Objective: To determine asthma outcomes in children undergoing adenotonsillectomy (T&A) for treatment of sleep-disordered breathing (SDB).
Asthma is one of the most common diseases in the pediatric population affecting 6.1 million children in the United States. 1 Sleep-disordered breathing (SDB), similarly, affects 1-3% of children. SDB encompasses a spectrum from partial obstruction generating snoring to increased upper airway resistance to continuous episodes of complete upper airway obstruction or obstructive sleep apnea (OSA). While SDB and asthma are considered to be separate diagnoses, a growing body of literature has begun to suggest a correlation between the two. 2 The pathophysiology of these disease processes is similar as neural input, inflammation, and anatomic factors such as obesity can contribute to both. 3 Preliminary work by our group showed that the prevalence of snoring was significantly higher in asthmatic children (35.5%) compared to non-asthmatic children (15.7%) and the prevalence of a positive Pediatric Sleep Questionnaire (PSQ) score was significantly higher in asthmatic children (25.9%) compared to non-asthmatic children (10.6%) (P < 0.001 for both). 4 The effect of asthma was "dosedependent" as children with more severe asthma had increased odds ratios for snoring and a positive PSQ. A systematic review by Brockmann et al. 5 of 17 studies encompassing 45 155 patients also demonstrated a significant association between asthma and SDB.
Median (range) prevalence of SDB was 23.9% (7.1-77.3%) in children with asthma compared to 16.7 (5.1-69.5%) in children without asthma (P < 0.0001).
A few preliminary studies have evaluated asthma outcomes after adenotonsillectomy (T&A). Findings from these studies have been summarized in two recent systematic reviews, 6, 7 and both reported clinically significant reductions in markers of asthma severity after surgery. Bhattarjee et al. 8 conducted a longitudinal database study of 13 506 asthmatic children who underwent T&A and 27 012 age-, sex-, and geographically-matched control asthmatic children who did not undergo surgery. They found significant reductions in asthma exacerbations, acute status asthmaticus, asthma-related emergency room visits, asthma-related hospitalizations, and asthma prescription refills in the T&A children but no significant reductions in these outcomes in the control children. Kheirandish-Gozal et al. 9 conducted a retrospective analysis of 92 poorly controlled asthmatic children.
Positive polysomnography (PSG) was found in 63% of these children.
Data from 35 of the OSA children 1-year after T&A was compared to 24 children without OSA and there was a significant decrease in asthma exacerbations (4.1 ± 1.3 to 1.8 ± 1.4/year, P < 0.0001) in the OSA children after T&A compared to no change in the non-OSA children. Levin et al. 10 evaluated 66 children with asthma and 64 control children without asthma who underwent T&A. Mean asthma control test scores improved 6 months after surgery and there were significant reductions in the rates of emergency room visits, oral corticosteroid courses, missed days from school from asthma, total parental missed days of work due to illness and circulating chitinase activity in the asthmatic children.
To date, there has been no prospective, controlled study evaluating asthma outcomes after T&A with a control group consisting of asthmatic children not undergoing surgery. The ideal control group would be asthmatic children with SDB not undergoing T&A, but this study design is not possible as withholding treatment would not be ethical. It is still important to control for improvements in asthma control over time. Our hypothesis is that asthmatic children undergoing T&A for treatment of SDB will demonstrate improvement in asthma outcomes using a validated asthma assessment measure, the Childhood Asthma Control Test (C-ACT), as compared to asthmatic children not undergoing surgical treatment for SDB.
| MATERIALS AND METHODS
This is a prospective, controlled study of asthma control in asthmatic children undergoing T&A for treatment of SDB matched by asthma severity to control children not receiving T&A. National Heart, Lung, and Blood Institute (NHBLI) Guidelines. after surgery for the study subjects and 6 months after enrollment for the control subjects.
| Questionnaires

| Childhood Asthma Control Test (C-ACT)
The C-ACT for ages 4 through 11 is a 7-item questionnaire that is completed by both the parent and child assessing asthma symptoms (daytime and nocturnal) and the effect of asthma on daily functioning in the previous 4 weeks. Each item includes 4-6 responses corresponding to a Likert-type rating. Responses for each item are summed to yield a score ranging from 0 (poor control of asthma) to 27
(complete control of asthma). A C-ACT score of ≤19 is defined as having uncontrolled asthma. based on a validity study that suggested optimal sensitivity and specificity at the 0.33 cut-off. 14 The PSQ has also been re-validated in a cohort of children with asthma. 15 
| Statistical analysis
The sample size estimation was based on comparison of the difference in C-ACT scores between T&A subjects and controls 6 months after surgery or 6 months after enrollment. Based on the results obtained by Busino et al., 16 we expected the difference in mean follow-up C-ACT scores between the two groups to be 2.2. The SD for both groups was estimated to be 4.0 based on the studies of ACT scores in somewhat to well-controlled asthma patient populations (Liu et al. 13 and Shi et al. 17 ).
Using a two-sided t-test with a significance level of 0.05 and a power of 90%, 71 patients were required for each group. Assuming a drop-out rate of 13%, it was planned that 80 patients per group would need to be recruited. While 80 T&A subjects were recruited, only 62 control subjects were recruited as research assistants were no longer available after August 2017. Table 1 . In both groups, mean age was 6.8 years, about 60% were male, and most were black. ASC classification was intermittent in about 60%, mild persistent in about 30%, and moderate persistent in about 10%. Fifty-five percent of the T&A subjects were overweight or obese compared to 45% of the control subjects.
Polysomnography was performed in 52 of the T&A subjects and the median (range) apnea-hypopnea index was 8.4 (0.5-41). Seventy-five of the T&A subjects had follow-up at a mean (SD) of 6.2 (1.4) months, while all 62 of the control subjects had follow-up at a mean (SD) of 6.5
(1.9) months.
C-ACT scores are presented in but did differ at follow-up (P = 0.006). There was significant improvement over time in both groups (T&A P < 0.001; control P = 0.030).
Forty-seven percent of the T&A group had scores ≤19 at entry while 15% had scores ≤19 at follow-up, compared to 37% and 32% in the control group.
Asthma outcome measures including the number of asthma exacerbations, number of courses of systemic steroids, number of emergency room visits and the number of hospitalizations in the 6 months prior to entry and follow-up were small for both groups. The median number of asthma exacerbations was 1 for both groups at entry and 0 for both groups at follow-up, while the median numbers of the other outcomes was 0 at both entry and follow-up for both groups (Table 3) . When only subjects with moderate or severe persistent asthma were evaluated, the number of asthma exacerbations and courses of systemic steroids were higher but there were only eight patients in each group.
Because of the large number of 0 values, the asthma outcomes were dichotomized as 0 versus >0 for the analysis. Statistical modeling did not demonstrate significant group by time interactions for any of the asthma outcomes. For any asthma exacerbations, groups did not differ significantly at either time point (entry P = 0.367; follow-up P = 0.327). There was significant improvement over time in both groups (T&A P < 0.001; control P = 0.002). For any steroid use, groups did not differ significantly at entry (P = 0.802) but differed at follow-up (P = 0.043). There was significant improvement over time in the T&A group (P < 0.001) but not in the control group (P = 0.083). For any emergency room visits, groups differed significantly at entry (P = 0.034) but not at follow-up (P = 0.053). There was significant improvement over time in both groups (P = 0.005 both tests). For any hospitalizations, groups differed significantly at entry (P = 0.035) but not at follow-up (P = 0.347). There was significant improvement over time in the control group (P = 0.048) but not in the T&A group (P = 0.348). (10) 36 (45) 1 (1) 2 (3) 32 (52) 7 (11) 21 (34) 0 (0) Hypertension, no. (%) 16 (20) 8 (13) Allergies, no. There was a significant improvement over time in both groups. b There was no significant difference in score between groups at entry, but there was a significant difference at follow-up. for the control group. There was a significant group by time interaction (P < 0.001). Simple effects analysis showed that group means differed at entry (P < 0.001) but did not differ at follow-up (P = 0.389). There was significant change over time in both groups (T&A P < 0.001; control P = 0.009). 86% of the T&A group had scores >0.33 at entry while 17% had scores >0.33 at follow-up, compared to 32% at both entry and follow-up for the control group.
Multivariate analysis evaluating study group, race/ethnicity, prematurity, BMI classification, allergy, insurance status, ASC, and baseline PSQ score as predictors of the change in C-ACT identified only baseline PSQ and study group as significant predictors.
Controlling for other terms in the model (N = 136), baseline PSQ was a significant predictor of change in C-ACT (P = 0.003 for a quadratic term). A Loess plot of the bivariate relationship between these two variables is presented in Figure 1 . Study group was also an independent predictor (P = 0.021); adjusted mean change in C-ACT was 8.0 (95% CI 5.8-10.2) for the T&A subjects versus 5.8 (95% CI 3.6-8.0) for the control subjects.
| DISCUSSION
Our results demonstrate that there was a significant improvement in our primary outcome measure, the C-ACT score, in asthmatic children after undergoing T&A for treatment of SDB compared to asthmatic control children not undergoing surgery. At entry 47% of the T&A subjects had uncontrolled asthma (C-ACT ≤19) compared to only 15%
at follow-up, while 37% of the control subjects had uncontrolled asthma at entry compared to 32% at follow-up. Our measure of SDB, the baseline PSQ, was a significant predictor of improvement in C-ACT scores. As expected, PSQ scores were significatly improved in the T&A group compared to the control group, as sugery was peformed for treatment of SDB. None of the additional variables in the model including race/ethnicity, prematurity, BMI classification, allergy, insurance status, and ASC were significant predictors of improvement TABLE 3 Asthma outcomes in adenotonsillectomy (T&A) subjects versus controls in the 6 months prior to entry and follow-up in C-ACT scores. The minimum important difference is 2 C-ACT points 18 which was achieved in both groups as the adjusted mean change in C-ACT was 8.0 (95% CI 5.8-10.2) for the T&A subjects vs 5.8 (95% CI 3.6-8.0) for the control subjects. It is expected that control subjects would experience improvements in C-ACT scores over time as they are receiving treatment for their asthma. Our results highlight the importance of incorporating a control group in the study design.
The C-ACT has been translated into several languages and has been validated as a useful tool for assessing asthma control and capturing its mult-dimensional nature. 13, [19] [20] [21] [22] C-ACT scores have been correlated with physicians' assessment of asthma control and decisions for asthma treatment 13, 20, 23 and higher scores have been associated with a decreased risk of asthma attacks and emergency room visits. 24 Our results are similar to two uncontolled studies. Levin et al. 10 demonstrated significant improvement in C-ACT scores six months after T&A with a median increase from 22 to 25 (P < 0.001) and
Busino et al. 16 demostrated signifcant improvements in C-ACT scores in 93 asthmatic patients 1 year after T&A (P < 0.01).
Although there were significant improvements in C-ACT scores, there were minimal improvements in the asthma clinical outcomes.
Despite (looking at uncorrected P-values) the intriguing-looking differences between groups across time in the asthma exacerbations, steroid use and hospitalization outcomes, the absence of significant group by time interaction, plus the observational nature of the study, make it difficult to make confident statements about these outcomes.
Asthma hospitalizations were actually significantly improved at followup in the control subjects compared to the T&A subjects but very few subjects in either group were hospitalized over the course of the study.
Overall, the asthma outcomes evaluated were very infrequent in both groups. Eighty-nine percent of the T&A subjects and 87% of the control subjects had intermittent or mild persistent asthma, so it is not surprising that the number of the outcomes was small. The small numbers of subjects with moderate or severe persistent asthma precluded a statistical analysis of only poorly controlled asthma subjects.
Levin et al. 10 controlled asthmatics in whom these clinical outcomes would be expected to be more frequent than in children not so severely affected. Their data were also collected by chart review, so it is subject to the limitations of a retrospective study design including the potential for selection bias and the need to rely on clinical records. Bhattarjee et al. 8 found significant reductions in asthma exacerbations, acute status asthmaticus, asthma-related emergency room visits, and asthma-related hospitalizations in children who underwent T&A while no changes were found in untreated children.
This was a database study so the sample size was extremely large.
Strengths of the study include its prospective nature, the inclusion of a control group not undergoing T&A matched to the T&A patients by asthma severity using NHBLI guidelines and the use of a validated assessment of asthma severity, the C-ACT. The greatest limitation was the the inability to use a control group of asthmatic children with SDB not undergoing T&A as withholding treatment would not be ethical.
The PSQ was also used instead of PSG for assessment of SDB as the cost and inconvenience of PSG precluded its use for a study of this magnitude. The PSQ has been validated for research purposes 14, 15 and has been used instead of PSG in studies with similar sample sizes. 4, 25 The majority of our sample was also African American/Afro-Carribean so the generalizability of our findings to other racial/ethnic groups may be limited. Asthma and SDB are more common in African American children and morbidities are higher in African American children compared to Caucasian children. Due to staffing issues, we were unable to reach our estimated sample size in the control subjects. Our sample size was also not large enough and did not include enough children with moderate or severe persistent asthma to evaluate the asthma clinical outcomes. The control subjects were not evaluated for adenotonsillar hypertrophy. The inflammation associated with adenotonsillar hypertophy may trigger lower airway inflammation separate from SDB that was not evaluated in this study.
In summary, our results demonstrate that treatment of SDB improves asthma outcomes as measured by the C-ACT. Our results support findings of two systematic reviews and several prelminary studies. Our findings suggest that children with asthma, particularly uncontrolled asthma, should be evaluated and treated for SDB.
